116 related articles for article (PubMed ID: 6347666)
1. 19-Hydroxyandrostenedione: evidence for a new class of sodium-retaining and hypertensinogenic steroids.
Sekihara H
Endocrinology; 1983 Sep; 113(3):1141-8. PubMed ID: 6347666
[TBL] [Abstract][Full Text] [Related]
2. 6 beta-Hydroxyandrostenedione: evidence for a new hypertensinogenic agent.
Sekihara H
Clin Exp Hypertens A; 1983; 5(1):1-9. PubMed ID: 6339119
[TBL] [Abstract][Full Text] [Related]
3. 19-Hydroxyandrostenedione: a potent hypertensinogenic steroid in man.
Sekihara H
J Steroid Biochem; 1983 Jul; 19(1A):353-8. PubMed ID: 6310235
[TBL] [Abstract][Full Text] [Related]
4. 19-hydroxyandrostenedione as a new hypertensinogenic agent.
Sekihara H
J Steroid Biochem; 1982 Feb; 16(2):329-31. PubMed ID: 7043093
[TBL] [Abstract][Full Text] [Related]
5. A reevaluation of the mineralocorticoid and hypertensinogenic potential of 19-hydroxyandrostenedione.
Gomez-Sanchez EP; Gomez-Sanchez CE
Endocrinology; 1986 Jun; 118(6):2582-7. PubMed ID: 3698922
[TBL] [Abstract][Full Text] [Related]
6. 19-Hydroxyandrostenedione amplifies the hypertensive action of mineralocorticoids in rats.
Sekihara H; Yazaki Y; Kojima T
J Endocrinol; 1993 Jul; 138(1):31-40. PubMed ID: 7852890
[TBL] [Abstract][Full Text] [Related]
7. 19-hydroxyandrostenedione and 6 beta-hydroxyandrostenedione: new steroids regulated by the renin-angiotensin system in man.
Sekihara H
J Steroid Biochem; 1984 Jan; 20(1):383-5. PubMed ID: 6708521
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the hypertensinogenic action of 19-hydroxyandrostenedione by aromatase inhibitor, delta 1-testololactone.
Sekihara H; Yonemitsu K; Takaku F
Endocrinology; 1987 Dec; 121(6):1931-6. PubMed ID: 3678133
[TBL] [Abstract][Full Text] [Related]
9. [Studies on the pressor mechanism of 19-hydroxyandrostenedione].
Honda M; Minato M; Takayama R; Nagashima Y; Watanabe M; Izumi Y; Fukuda N; Soma M; Shiratsuchi T; Watanabe Y
Nihon Naibunpi Gakkai Zasshi; 1989 Jan; 65(1):18-31. PubMed ID: 2524410
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II induces the release of 19-hydroxyandrostenedione in man.
Sekihara H; Torii R; Osawa Y; Takaku F
J Clin Endocrinol Metab; 1985 Aug; 61(2):291-6. PubMed ID: 2989318
[TBL] [Abstract][Full Text] [Related]
11. Plasma 19-hydroxyandrostenedione is elevated in patients with high renin essential hypertension.
Sekihara H; Yonemitsu K; Yazaki Y
Clin Endocrinol (Oxf); 1993 Nov; 39(5):557-60. PubMed ID: 8252745
[TBL] [Abstract][Full Text] [Related]
12. Selective 19-hydroxylase inhibition by an aromatase inhibitor, 4-hydroxyandrostenedione.
Griffing GT; Holbrook M; Melby JC; Brodie AH
Clin Physiol Biochem; 1988; 6(3-4):171-8. PubMed ID: 3203487
[TBL] [Abstract][Full Text] [Related]
13. [A comparative study of C19 steroid-induced hypertension and deoxycorticosterone acetate (DOCA)-salt hypertension].
Minato M; Honda M; Hatano M
Nihon Naibunpi Gakkai Zasshi; 1990 Jan; 66(1):29-41. PubMed ID: 2307256
[TBL] [Abstract][Full Text] [Related]
14. 19-Oxoandrost-4-ene-3,17-dione amplifies the action of aldosterone.
Sekihara H; Yazaki Y
J Steroid Biochem Mol Biol; 1993 Jul; 46(1):69-72. PubMed ID: 8338792
[TBL] [Abstract][Full Text] [Related]
15. Time-related changes in plasma adrenal steroids during treatment with spironolactone in primary aldosteronism.
Sakamoto H; Ichikawa S; Sakamaki T; Nakamura T; Ono Z; Takayama Y; Murata K
Am J Hypertens; 1990 Jul; 3(7):533-7. PubMed ID: 2194510
[TBL] [Abstract][Full Text] [Related]
16. Selective hypoaldosteronism with hyperreninemia in a diabetic patient.
Morimoto S; Kim KS; Yamamoto I; Uchida K; Takeda R; Kornel L
J Clin Endocrinol Metab; 1979 Nov; 49(5):742-7. PubMed ID: 489714
[TBL] [Abstract][Full Text] [Related]
17. Effect of spironolactone on electrolytes, renin, ACTH and corticosteroids in the rat.
Chabert PR; Guelpa-Decorzant C; Riondel AM; Vallotton MB
J Steroid Biochem; 1984 Jun; 20(6A):1253-9. PubMed ID: 6087026
[TBL] [Abstract][Full Text] [Related]
18. Role of glucocorticoid in the development of glycyrrhizin-induced hypertension.
Kageyama Y; Suzuki H; Saruta T
Clin Exp Hypertens; 1994 Nov; 16(6):761-78. PubMed ID: 7858558
[TBL] [Abstract][Full Text] [Related]
19. Plasma corticosteroid concentrations during spironolactone administration: evidence for adrenal biosynthetic blockade in man.
Tuck ML; Sowers JR; Fittingoff DB; Fisher JS; Berg GJ; Asp ND; Mayes DM
J Clin Endocrinol Metab; 1981 Jun; 52(6):1057-61. PubMed ID: 6262360
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid hypertension in childhood.
New MI; Levine LS
Mayo Clin Proc; 1977 May; 52(5):323-8. PubMed ID: 323586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
